GenSight Biologics SA is a clinical-stage biopharmaceutical company headquartered in Paris, France, focused on developing gene therapies for retinal neurodegenerative diseases. Founded in 2012, the company concentrates its research and development on innovative treatments designed to restore or preserve vision in patients suffering from inherited optic neuropathies and retinal disorders. GenSight is publicly traded on Euronext Paris and is available over-the-counter in the United States under the symbol GSGTF.
The company’s lead product, LUMEVOQ (GS010), is a one-time intravitreal injection of an adeno-associated viral vector carrying the ND4 gene, intended to treat Leber’s Hereditary Optic Neuropathy (LHON) associated with the m.11778G>A mutation. In September 2022, LUMEVOQ received CE marking in the European Union, positioning it as the first approved gene therapy for this rare mitochondrial disease. GenSight has also submitted a biologics license application (BLA) to the U.S. Food and Drug Administration, aiming to secure approval in North America.
Beyond LHON, GenSight is advancing its next-generation program, GS030, which combines optogenetic gene therapy with specialized wearable visual stimulation goggles. This approach is being explored for broader indications, including retinitis pigmentosa and geographic atrophy, with the goal of reactivating dormant retinal cells through light-sensitive proteins. The company operates research facilities in Paris and maintains a presence in the United States to support clinical initiatives and regulatory interactions.
Under the leadership of Chief Executive Officer Bernard Gilly, GenSight Biologics has cultivated strategic collaborations with academic institutions and clinical centers across Europe and North America. The management team comprises seasoned executives with expertise in gene therapy, ophthalmology, and pharmaceutical development, guiding the company through pivotal clinical milestones toward potential global commercialization of its ophthalmic gene therapies.
AI Generated. May Contain Errors.
Free GSGTF Stock Alerts